Paltalk, Inc. (PALT) received a $65.7 million verdict against Cisco Systems, Inc. (CSCO) in a patent infringement lawsuit. Despite the substantial award, Paltalk’s shares are trading lower due to potential post-trial proceedings and significant litigation costs. The company recently reported a decline in revenue and a net loss for the second quarter.
Novartis AG, the pharmaceutical giant, has suffered a legal setback in its efforts to prevent the launch of a generic version of its blockbuster heart-failure drug, Entresto. A federal court ruled against Novartis’ request to block MSN Pharmaceuticals from launching its generic version, citing a low likelihood of winning the patent infringement lawsuit. While the ruling temporarily suspends MSN’s sales pending an appeal, it marks a significant blow to Novartis’ efforts to protect its intellectual property and maintain market dominance for Entresto, its top-selling drug.
The Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has declined to initiate Inter Partes Review (IPR) of all patents asserted by Vicor Corporation in its complaint against Delta Electronics (Delta). The decision follows an ITC investigation into power converter modules allegedly infringing Vicor’s patents. Delta had attempted to challenge the validity of the patents through IPR petitions, but the PTAB concluded that Delta was unlikely to succeed in its challenges. The patents in question cover innovative technologies in power conversion, including digital control of switching resonant power converters, non-isolated, fixed-ratio bus converters, and power converters designed for symmetrical heat distribution. Vicor’s CEO, Dr. Patrizio Vinciarelli, hailed the PTAB’s decision, stating that it debunks expert opinions proffered by Delta in its attempts to invalidate Vicor patents.
